Krystal Biotech
KRYS
308.89
-6.93
-2.19%
Krystal Biotech
US · KRYS
#1515 by market cap
Listed 2017
308.89
-6.93
-2.19%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Citi moved from Hold to Buy on 2026-01-06.
Analyst consensus 6 analysts
Buy
Avg price target 393.17 +27.3%
Price target rangecurrent 308.89
Low361.00
Avg393.17
High441.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-06 | RBC Capital | -- | Buy | 375.00 |
| 2026-11-03 | TD Cowen | -- | Buy | 380.00 |
| 2026-11-03 | Citi | -- | Buy | 412.00 |
| 2026-11-02 | BofA Securities | -- | Buy | 390.00 |
| 2026-11-02 | Citi | -- | Buy | 412.00 |
| 2026-11-02 | H.C. Wainwright | -- | Buy | 361.00 |
| 2026-11-02 | RBC Capital | -- | Buy | 375.00 |
| 2026-10-21 | TD Cowen | -- | Buy | 403.00 |
| 2026-10-16 | Citi | -- | Buy | 416.00 |
| 2026-10-15 | Citi | -- | Buy | 416.00 |
| 2026-10-15 | H.C. Wainwright | -- | Buy | 361.00 |
| 2026-10-08 | RBC Capital | -- | Buy | 400.00 |
| 2026-09-24 | Goldman Sachs | -- | Buy | 441.00 |
| 2026-09-21 | BofA Securities | -- | Buy | 400.00 |
| 2026-08-14 | RBC Capital | -- | Buy | 400.00 |
| 2026-08-11 | Wolfe Research | -- | Hold | -- |
| 2026-08-04 | Citi | -- | Buy | 386.00 |
| 2026-08-03 | TD Cowen | -- | Buy | 403.00 |
| 2026-08-03 | William Blair | -- | Buy | -- |
| 2026-08-03 | BofA Securities | -- | Buy | 392.00 |
| 2026-08-03 | H.C. Wainwright | -- | Buy | 361.00 |
| 2026-07-22 | William Blair | -- | Buy | -- |
| 2026-07-13 | BofA Securities | -- | Buy | 396.00 |
| 2026-07-13 | Jefferies | -- | Buy | 474.00 |
| 2026-06-18 | TD Cowen | -- | Buy | 403.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-01-06 | Citi | Hold → Buy | 309.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | -- | ±8.92% | -10.95% (beat) |
| 2026/Q2 | 2026-08-03 | -- | ±10.66% | -8.37% (in line) |
| 2026/Q1 | 2026-05-04 | -- | ±8.29% | +7.86% (in line) |
| 2025/Q4 | 2026-02-17 | -- | ±8.15% | +4.12% (in line) |
| 2025/Q3 | 2025-11-03 | -- | ±11.42% | +0.17% (in line) |
| 2025/Q2 | 2025-08-04 | -- | ±11.51% | -14.04% (beat) |
| 2025/Q1 | 2025-05-06 | -- | ±11.04% | -14.06% (beat) |
| 2024/Q4 | 2025-02-19 | -- | ±13.26% | +12.43% (in line) |
| 2024/Q3 | 2024-11-04 | -- | ±13.93% | -3.14% (in line) |
| 2024/Q2 | 2024-08-05 | -- | ±15.03% | -5.85% (in line) |
| 2024/Q1 | 2024-05-06 | -- | ±13.03% | -2.58% (in line) |
| 2023/Q4 | 2024-02-26 | -- | ±16.98% | +41.02% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Krystal Biotech discussion 0 comments